Tris Pharma acquires Pfizer's NextWave Pharmaceuticals

• Privately held Tris Pharma acquires Pfizer (NYSE:PFE +0.5%) subsidiary NextWave Pharmaceuticals for an undisclosed sum. The deal includes two candidates for attention-deficit/hyperactivity disorder (ADHD).
• Pfizer acquired NextWave in November 2012. ADHD treatment Quillivant XR was approved in the U.S. in September 2012. Earlier this year, the product, along with Quillichew ER, was in short supply due to a manufacturing issue.